Theralase Technologies Inc. (TLT.V)
| Previous Close | 0.1950 |
| Open | 0.2100 |
| Bid | 0.1950 x 0 |
| Ask | 0.2000 x 0 |
| Day's Range | 0.2000 - 0.2100 |
| 52 Week Range | 0.1400 - 0.3100 |
| Volume | |
| Avg. Volume | 159,018 |
| Market Cap | 47.859M |
| Beta (5Y Monthly) | 1.58 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | Aug 27, 2024 - Sept 02, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIRERutherrin(R) Increases Efficacy of Immunotherapy Preclinically
TORONTO, ON / ACCESSWIRE / June 18, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated ...
- ACCESSWIRE
Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R)
TORONTO, ON / ACCESSWIRE / April 14, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated ...
ACCESSWIRERutherrin(R) Increases Efficacy of Chemotherapy
TORONTO, ON / ACCESSWIRE / June 12, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated ...
